• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Clarivate (CLVT) Faces A Fresh Valuation Test Following Its AI Patent Deal

    Simply Wall St·10/17/2026 14:34:21
    語音播報

    Clarivate (CLVT) is back in focus after announcing a co-development deal with intellectual property law firm Sterne, Kessler, Goldstein & Fox to build AI-driven tools for patent drafting and workflow.

    Recent trading reflects that tension between fresh product news and a tough history for holders. Clarivate’s 1-day share price return of 1.72% and 7-day share price return of 9.94% around the AI partnership sit against a 30-day share price decline of 5.35% and a year-to-date share price drop of 45.37%, while total shareholder return is down 50.56% over one year and 92.03% over five years. This signals short term momentum picking up within a much tougher long term experience for investors.

    Scan how Clarivate’s AI push compares with other potential breakouts across vetted 37 AI small caps shaping the next wave of intellectual property and data tools.

    So is Clarivate’s latest bounce a real readout on a leaner, IP focused business after selling Life Sciences & Healthcare, or just a quick mood swing in a stock that has fallen hard? The valuation work starts here.

    Most Popular Narrative: 40% Undervalued

    Clarivate’s most followed valuation story pegs fair value at $2.97 per share, well above the last close at $1.77. This frames the AI and restructuring headlines against a much lower trading price.

    Rapid expansion and adoption of AI-driven product innovation across all segments (including new AI-powered analytics in Web of Science, Derwent, and Cortellis) enhances product differentiation and workflow integration, driving higher pricing, customer retention, and potentially expanding gross margins.

    See why 5 investors see Clarivate as 40% undervalued.

    Result: Fair Value of $2.97 (UNDERVALUED)

    Still, Clarivate’s heavy debt load and pressure on higher education budgets could easily derail the rebuilding story that underpins that 40% undervalued narrative.

    Find out about the key risks to this Clarivate narrative.

    Next Steps

    Feeling mixed about Clarivate after all that? This is exactly the moment to review the full risk and reward picture yourself with 3 key rewards and 1 important warning sign

    Looking for more investment ideas beyond Clarivate?

    If Clarivate has your attention, do not stop there. Broaden your watchlist with other clear, data driven ideas that could sharpen your overall portfolio.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.